Recent market fluctuations have been significant, which might make it easy to forget the glorious moments of the stock market. However, when the market experiences a sell-off, it is actually an excellent opportunity to discover potential stocks. Several experts have recently joined forces to recommend three companies with long-term potential. These companies may continue to grow in the coming years.

First, CRISPR Therapeutics is known for its gene editing techniques. Although there has not been significant performance in the past year or two, the company has indeed made major achievements in the treatment of blood diseases. The blood disorder treatment drug Casgevy launched by CRISPR this year has almost no competitors in the market, and it is said that the total sales are expected to exceed one billion dollars. Although the development speed is slow and revenue has not yet poured in significantly, this lays a foundation for the company's long-term profitability. Moreover, the company is developing new therapies for conditions such as diabetes. With so many potential drug trials being successful, there may be numerous brilliant moments in clinical and regulatory aspects in the next five years, so there is great anticipation for the company's future trajectory.

Next, Summit Therapeutics is gearing up for a highly promising drug. The company is collaborating with the Chinese pharmaceutical company Akeso to develop an immunotherapy called ivonescimab, which has achieved quite competitive trial results in the field of cancer. However, in the global market, Summit holds the sales rights for ivonescimab, which will be a significant source of profit growth. Summit is currently conducting multiple trial phases, particularly trials for lung cancer treatment. Once approved, this drug is expected to become a market blockbuster, thereby driving rapid growth for the company.

Finally, despite the current decline in stock prices, Viking Therapeutics has not stalled its new drug development achievements. The company is conducting multiple drug trials, including a GLP-1 drug for obesity, which could lead to a rebound in its stock price if successful. Additionally, other drugs are entering new trial phases, increasing the potential for the company's future development. Venture capitalists may find that now is a good entry point, as this investment is expected to yield returns in the long run.

The stock market is always full of uncertainty, but perhaps a more optimistic future can be seen with these companies. No matter how you look at it, the development paths of these three companies are worth paying close attention to. Any thoughts? Leave a comment to chat!